News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Plasma Cell Neoplasms → cancer profile · × Clear filters
Treatment Decisions in Multiple Myeloma
The New England Journal of Medicine published a comprehensive clinical-practice review on treatment decision-making in multiple myeloma, synthesizing current evidence across frontline and relapsed settings. The review, spanning 17 pages in the journal’s September 2026 issue, likely addresses evolving standards including quadruplet induction regimens, bispecific antibodies, and CAR-T sequencing in …
MedPage Today roundup: FDA approves ropeginterferon alfa-2b for essential thrombocythemia — first new therapy for this myeloproliferative neoplasm since 1997
The FDA approved ropeginterferon alfa-2b (Besremi) for adults with essential thrombocythemia, marking the first new therapy for this chronic myeloproliferative neoplasm since anagrelide's approval in 1997. The roundup also highlights emerging data on AI-assisted mammography screening and a positive phase III trial result in multiple myeloma. Although Besremi was previously approved for polycythemi…
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
The International Myeloma Working Group has updated its recommendations on solitary plasmacytomas - localized tumours of clonal plasma cells, either in bone or extramedullary, with no more than minimal marrow involvement (under 10% clonal plasma cells) and no myeloma-defining events. The core message is prognostic: about 50% of patients progress to symptomatic myeloma within 5 years of definitive …
FDA grants accelerated approval to iberdomide, the first CELMoD, combined with daratumumab and dexamethasone in multiple myeloma
On 13 August 2026 the FDA granted ACCELERATED approval to iberdomide (Zenbexus), the first cereblon E3 ligase modulator (CELMoD), in COMBINATION with daratumumab and hyaluronidase-fihj and dexamethasone — not as monotherapy — for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. In the randomised, open-…
Phase 3 MonumenTAL-3: talquetamab plus daratumumab extends progression-free survival in relapsed or refractory multiple myeloma (HR 0.28)
In the randomized phase 3 MonumenTAL-3 trial (864 patients with relapsed or refractory multiple myeloma after at least one prior line, 287 per arm), the GPRC5D-directed bispecific antibody talquetamab — combined with daratumumab and pomalidomide or with daratumumab alone — outperformed daratumumab-pomalidomide-dexamethasone. At 24 months, progression-free survival was 81.3% and 77.6% versus 51.2% …
Local AI agent brings tumor board expertise to hematological malignancies
Nature Cancer reports a locally deployed AI agent, running on a hospital's own infrastructure, intended to reproduce the work of a multidisciplinary tumour board in haematological malignancies. Local deployment means patient data never leave the institution, which is the main advantage claimed over cloud-based systems. The available report does not state how many cases were assessed, how the syste…